Q-omics provides the consensus-scored TTC26 profile across patient tissues and cancer cell-line models. TTC26 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TTC26 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TTC26 RNA expression shows 20,335 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where TTC26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC26 survival associations across molecular data types. TTC26 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC26 RNA expression–survival associations across cancer types. High TTC26 expression shows unfavorable associations in KICH, LIHC, LGG and ACC, but favorable associations in KIRC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TTC26 RNA expression.
This table summarizes TTC26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC26 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, KIRP, BLCA and STAD. The COAD box plot shows higher TTC26 RNA expression in tumor versus normal tissue (log2 FC = +1.577, t-test p < 0.001).
This table shows molecular features associated with TTC26 in patient tissues and cancer cell lines. In patient samples, TTC26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
